PGEN
ACHAT TOTAL: 3 411 titres (~24 661,53 $ US) VENTE TOTALE: 185 000 titres (~1 376 400,00 $ US)
- Insiders
- KINDLER JEFFREY B, AGEE NANCY H
- Total bought
- $24,662
- Total sold
- $1,376,400
- Last activity
- 2026-08-26
- Last synced
-
2026-09-01 10:09:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-01
PGEN presents a meaningful earnings catalyst driven by PAPZIMEOS's FDA approval and strong Q2 revenue, but the extremely weak financial health scores (25 liquidity, 15 fundamental trend) reveal deep structural fragility…
The first sentence of the analysis written for PGEN on 2026-09-01 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 37.1% | -8.7% | 1.7% | 76.4% | -276.2% | |
| Ebit Margin | -2548.2% | -3261.7% | -1540.5% | -272.0% | -640.7% | |
| Ebitda Margin | -2515.2% | -3146.4% | -1433.3% | -232.0% | -544.2% | |
| Operating Profit Margin | -1100.8% | -3440.2% | -1602.5% | -281.4% | -644.5% | |
| Pretax Profit Margin | -2588.2% | -3261.9% | -1548.0% | -297.2% | -777.8% | |
| Continuous Operations Profit Margin | -2588.2% | -3216.2% | -1540.6% | -296.5% | -776.7% | |
| Net Profit Margin | -2588.2% | -3216.2% | -1540.6% | 105.2% | -646.0% | |
| Bottom Line Profit Margin | -4436.6% | -3216.2% | -1540.6% | -296.5% | -776.7% | |
| Current Ratio | 3.089 | 4.759 | 2.991 | 1.502 | 4.521 | |
| Quick Ratio | 2.832 | 4.759 | 2.991 | 1.499 | 4.512 | |
| Solvency Ratio | -1.823 | -1.140 | -2.742 | 0.436 | -0.311 | |
| Cash Ratio | 0.810 | 1.372 | 0.330 | 0.062 | 1.051 | |
| Price To Earnings Ratio | -2.965 | -2.383 | -3.436 | -4.606 | -7.894 | |
| Price To Earnings Growth Ratio | -0.015 | -0.116 | -0.189 | 0.155 | 0.146 | |
| Forward Price To Earnings Growth Ratio | -0.015 | -0.116 | -0.189 | 0.155 | 0.146 | |
| Price To Earnings Diluted Ratio | -2.965 | -2.383 | -3.436 | -3.800 | -7.894 | |
| Price To Earnings Diluted Growth Ratio | -0.015 | -0.116 | 1.374 | 0.255 | 0.146 | |
| Price To Book Ratio | 60.909 | 7.786 | 2.765 | 2.412 | 6.835 | |
| Price To Sales Ratio | 131.524 | 76.396 | 52.639 | 11.318 | 51.426 | |
| Price To Free Cash Flow Ratio | -14.179 | -3.907 | -4.786 | -4.353 | -11.643 | |
| Price To Operating Cash Flow Ratio | -14.501 | -4.398 | -4.896 | -4.682 | -13.155 | |
| Debt To Assets Ratio | 0.628 | 0.038 | 0.047 | 0.238 | 0.528 | |
| Debt To Equity Ratio | 4.700 | 0.143 | 0.060 | 0.407 | 1.771 | |
| Debt To Capital Ratio | 0.825 | 0.125 | 0.057 | 0.289 | 0.639 | |
| Long Term Debt To Capital Ratio | 0.817 | 0.000 | 0.000 | 0.000 | 0.626 | |
| Financial Leverage Ratio | 7.490 | 3.772 | 1.275 | 1.711 | 3.352 | |
| Working Capital Turnover Ratio | 0.122 | 0.062 | 0.146 | 0.333 | 0.125 | |
| Operating Cash Flow Ratio | -2.354 | -3.168 | -2.912 | -0.827 | -1.610 | |
| Operating Cash Flow Sales Ratio | -9.070 | -17.369 | -10.752 | -2.417 | -3.909 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.023 | 1.126 | 1.023 | 1.076 | 1.130 | |
| Debt Service Coverage Ratio | -62.988 | -20,283.833 | -189.675 | -1.245 | -4.120 | |
| Interest Coverage Ratio | -27.567 | -22,504.833 | -213.158 | -11.179 | -4.903 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -1.505 | -1,072.519 | |
| Operating Cash Flow Coverage Ratio | -0.894 | -12.391 | -9.431 | -1.265 | -0.293 | |
| Capital Expenditure Coverage Ratio | -44.026 | -7.942 | -43.574 | -13.210 | -7.696 | |
| Dividend Paid And Capex Coverage Ratio | -44.026 | -7.942 | -43.574 | -13.210 | -7.696 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.509 | -2.234 | -3.667 | -5.624 | -11.428 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 37.0% | ▲45.8% | ▲71.0% |
| Ebit Margin | -2548.2% | ▲713.5% | ▼-895.6% |
| Ebitda Margin | -2515.2% | ▲631.2% | ▼-941.0% |
| Operating Profit Margin | -1100.8% | ▲2339.4% | ▲313.1% |
| Pretax Profit Margin | -2588.2% | ▲673.7% | ▼-893.6% |
| Continuous Operations Profit Margin | -2588.2% | ▲628.0% | ▼-904.6% |
| Net Profit Margin | -2588.2% | ▲628.0% | ▼-1011.0% |
| Bottom Line Profit Margin | -4436.6% | ▼-1220.4% | ▼-2383.3% |
| Current Ratio | 3.089 | ▼-1.671 | ▼-0.284 |
| Quick Ratio | 2.832 | ▼-1.927 | ▼-0.486 |
| Solvency Ratio | -1.823 | ▼-0.683 | ▼-0.707 |
| Cash Ratio | 0.810 | ▼-0.561 | ▲0.085 |
| Price To Earnings Ratio | -2.965 | ▼-0.582 | ▲1.292 |
| Price To Earnings Growth Ratio | -0.015 | ▲0.101 | ▼-0.011 |
| Forward Price To Earnings Growth Ratio | -0.015 | ▲0.101 | ▼-0.011 |
| Price To Earnings Diluted Ratio | -2.965 | ▼-0.582 | ▲1.131 |
| Price To Earnings Diluted Growth Ratio | -0.015 | ▲0.101 | ▼-0.344 |
| Price To Book Ratio | 60.910 | ▲53.124 | ▲44.768 |
| Price To Sales Ratio | 131.524 | ▲55.128 | ▲66.864 |
| Price To Free Cash Flow Ratio | -14.179 | ▼-10.273 | ▼-6.406 |
| Price To Operating Cash Flow Ratio | -14.502 | ▼-10.103 | ▼-6.175 |
| Debt To Assets Ratio | 0.628 | ▲0.590 | ▲0.332 |
| Debt To Equity Ratio | 4.700 | ▲4.558 | ▲3.284 |
| Debt To Capital Ratio | 0.825 | ▲0.700 | ▲0.438 |
| Long Term Debt To Capital Ratio | 0.817 | ▲0.817 | ▲0.528 |
| Financial Leverage Ratio | 7.490 | ▲3.718 | ▲3.970 |
| Working Capital Turnover Ratio | 0.122 | ▲0.060 | ▼-0.036 |
| Operating Cash Flow Ratio | -2.354 | ▲0.814 | ▼-0.180 |
| Operating Cash Flow Sales Ratio | -9.070 | ▲8.299 | ▼-0.366 |
| Free Cash Flow Operating Cash Flow Ratio | 1.023 | ▼-0.103 | ▼-0.053 |
| Debt Service Coverage Ratio | -62.988 | ▲20220.845 | ▲4045.384 |
| Interest Coverage Ratio | -27.567 | ▲22477.267 | ▲4524.761 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲214.805 |
| Operating Cash Flow Coverage Ratio | -0.894 | ▲11.497 | ▲3.961 |
| Capital Expenditure Coverage Ratio | -44.026 | ▼-36.084 | ▼-20.736 |
| Dividend Paid And Capex Coverage Ratio | -44.026 | ▼-36.084 | ▼-20.736 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.508 | ▼-3.275 | ▲0.184 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.27B | $299.9M | $327.7M | $304.5M | $733.7M | |
| Enterprise value | $1.34B | $275.8M | $327.2M | $351.1M | $887.3M | |
| EV / Sales | 138.55x | 70.28x | 52.56x | 13.05x | 62.20x | |
| EV / Op. cash flow | -15.28x | -4.05x | -4.89x | -5.40x | -15.91x | |
| EV / Free cash flow | -14.94x | -3.59x | -4.78x | -5.02x | -14.08x | |
| EV / EBITDA | -5.51x | -2.23x | -3.67x | -5.62x | -11.43x | |
| Net debt / EBITDA | -0.28x | 0.19x | 0.01x | -0.75x | -1.98x | |
| Current ratio | 3.09x | 4.76x | 2.99x | 1.50x | 4.52x | |
| Income quality | 0.35x | 0.54x | 0.70x | -2.30x | 0.60x | |
| Graham number | — | — | — | $1 | — | |
| Graham net-net | -$0 | -$0 | $0 | -$0 | -$1 | |
| Tax burden | 100.0% | 98.6% | 99.5% | -35.4% | 83.1% | |
| Interest burden | 101.6% | 100.0% | 100.5% | 109.3% | 121.4% | |
| Working capital | $77.9M | $80.9M | $45.8M | $39.5M | $122.0M | |
| Invested capital | $114.8M | $123.3M | $127.2M | $136.2M | $230.4M | |
| Return on assets | -160.0% | -86.9% | -63.5% | 13.1% | -25.6% | |
| Operating ROA | -70.6% | -91.1% | -54.4% | -26.3% | -27.3% | |
| Return on tangible assets | -181.4% | -103.8% | -114.5% | 21.0% | -34.1% | |
| Return on equity | -1198.6% | -327.8% | -80.9% | 22.4% | -85.9% | |
| Return on invested capital | -88.5% | -106.8% | -76.8% | -41.6% | -28.1% | |
| Return on capital employed | -89.3% | -109.1% | -77.9% | -55.1% | -28.3% | |
| Earnings yield | -19.7% | -42.1% | -29.3% | 9.3% | -12.6% | |
| Free cash flow yield | -7.1% | -25.6% | -20.9% | -23.0% | -8.6% | |
| Capex / Op. cash flow | -2.3% | -12.6% | -2.3% | -7.6% | -13.0% | |
| Capex / Depreciation | 62.4% | 189.7% | 23.0% | 45.7% | 52.7% | |
| Capex / Sales | 20.6% | 218.7% | 24.7% | 18.3% | 50.8% | |
| SG&A / Sales | 724.2% | 1052.1% | 649.2% | 178.4% | 0.0% | |
| R&D / Sales | 413.7% | 1352.1% | 780.9% | 175.3% | 336.0% | |
| Stock comp / Sales | 112.2% | 241.3% | 158.8% | 37.9% | 97.5% | |
| Intangibles / Total assets | 11.8% | 16.2% | 44.6% | 37.7% | 25.0% | |
| Days sales outstanding | 164d | 108d | 92d | 187d | 51d | |
| Days payables outstanding | 718d | 302d | 103d | 234d | 21d | |
| Operating cycle | 738d | 108d | 92d | 204d | 53d | |
| Cash conversion cycle | 20d | -194d | -11d | -30d | 32d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+324.8%EV / Sales ▲+97.1%EV / EBITDA ▼-146.6%EV / Op. cash flow ▼-11.230Earnings yield ▲+0.224
Profitability
Return on equity ▼-8.708Return on assets ▼-0.731Return on invested capital ▲+0.183Return on capital employed ▲+0.198Operating ROA ▲+0.205Income quality ▼-0.190Tax burden ▲+0.014
Efficiency
Days sales outstanding ▲+56.257Days payables outstanding ▲+415.563Operating cycle ▲+629.922Cash conversion cycle ▲+214.359Capex / Sales ▼-1.981R&D / Sales ▼-9.384
Balance-sheet strength
Current ratio ▼-1.671Net debt / EBITDA ▼-0.474Working capital ▼-2967000.000Invested capital ▼-8509000.000Intangibles / Total assets ▼-0.045
Change over 5 years
Valuation
Market cap ▲+73.6%EV / Sales ▲+122.8%EV / EBITDA ▲+51.8%EV / Op. cash flow ▲+0.634Earnings yield ▼-0.071
Profitability
Return on equity ▼-11.128Return on assets ▼-1.344Return on invested capital ▼-0.604Return on capital employed ▼-0.611Operating ROA ▼-0.434Income quality ▼-0.255Tax burden ▲+0.169
Efficiency
Days sales outstanding ▲+113.753Days payables outstanding ▲+696.445Operating cycle ▲+685.202Cash conversion cycle ▼-11.243Capex / Sales ▼-0.302R&D / Sales ▲+0.777
Balance-sheet strength
Current ratio ▼-1.432Net debt / EBITDA ▲+1.700Working capital ▼-44054000.000Invested capital ▼-115601000.000Intangibles / Total assets ▼-0.132
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-27 Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
- 2026-08-26 5 Biotech Stocks Worth Adding to Your Portfolio Now New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
- 2026-08-25 Precigen''s Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers Biotech in the News: The Longview The Company''s New Drug, the First FDA-Approved Therapy for Recurrent Respiratory Papillomatosis (RRP), is Delivering Strong Commercial Traction While Highlighting the Broader Potential of Its Proprietary AdenoVerse Therapeutic Platform in HPV-Associated Cancers GERMANTOWN, MD / ACCESS Newswire / August 25, 2026 / For Germantown, MD-based Precigen Inc. (NASDAQ:PGEN), the second quarter marked a commercial inflection. PAPZIMEOS (zopapogene imadenovec-drba) generated $53.1 million in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability.
- 2026-08-20 Reasons Why Investors Should Consider Betting on PGEN Stock Precigen''s Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.
- 2026-08-14 Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-08 Precigen: Has To Grow Into Its Valuation Precigen surged 266% on PAPZIMEOS FDA approval but now trades at a premium valuation near $2.24 billion. PAPZIMEOS, the sole revenue driver, reached $53.1 million in Q2 with COGS being just around $2.8 million. PGEN''s pipeline faces stiff competition, with most candidates showing weaker efficacy than approved or late-stage rivals.
- 2026-08-06 Precigen: ''Strong Buy'' Papzimeos Cash-Flow Breakeven In ''26, PRGN-2009 Advancement Precigen, Inc. is upgraded to a Strong Buy, driven by surging PAPZIMEOS revenues and FDA approval for recurrent respiratory papillomatosis (RRP). PGEN achieved profitability in Q2 2026 with PAPZIMEOS revenues doubling quarter-over-quarter to $53.1 million and secured seven years of U.S. market exclusivity. Potential European approval of PAPZIMEOS and expansion of the AdenoVerse Immunotherapy platform, notably PRGN-2009, could unlock significant new market opportunities.
- 2026-08-06 Arrowstreet Capital Limited Partnership Acquires Shares of 395,695 Precigen, Inc. $PGEN Arrowstreet Capital Limited Partnership acquired a new stake in shares of Precigen, Inc. (NASDAQ: PGEN) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 395,695 shares of the biotechnology company''s stock, valued at approximately $1,531,000. Arrowstreet Capital Limited Partnership owned
- 2026-08-05 Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript
- 2026-08-04 Precigen Q2 Earnings Call Highlights Precigen NASDAQ: PGEN reported a sharp increase in second-quarter revenue from its PAPZIMEOS launch, with the company reaching quarterly profitability less than a year after the therapy''s August 2025 FDA approval for adults with recurrent respiratory papillomatosis, or RRP.